play+e66809b67e, you do not have the variant we tested.
You could still have a variant not covered by this test.
··• 0 How To Use This Test
This test does not diagnose any health conditions. • To identify carrier status for ACCPN.
Limitations
• Does not test for all possible variants for the condition.
( @I Print )
• Does not report if someone has two copies of a tested variant.
Review the Carrier Status tutorial See Scientific Details

Important Ethnicities
• This test is most relevant for people of French Canadian descent.
You are likely not a earner.
This result is relevant for you because you have French Canadian ancestry.
•
We ruled out the most common variant for ACCPN in people of French Canadian descent.
You still have a chance of being a carrier for ACCPN.
You may still have up to a 1 in 22,000,000 chance of carrying a variant not covered by this test. 
How it's treated
There is currently no known cure. Treatment focuses on physical and occupational therapy as well as other forms of supportive care as symptoms worsen, often into adulthood.
Consider talking to a healthcare professional if you are concerned about your results. •This test cannot d1st,nguish which copy you received from wh,ch parent. Th,s test also cannot determ,ne whether multiple vana_ nts, 1f detected, were inherited from only one parent or from both parenH. This may impact how these variants are passed down.
23andMe always reports 9. E!n . <>. tYPE!S. based on the positive' strand of the human 9. E!ri_<>_(T) __ E! reference sequence (build 37). Other socrces sometimes report genotypes using the opposite strand.
Test Interpretation
Post-Test Carrier Risk
This report provides an estimate of the chances of still being a carrier for people who do not have the variant(s) tested. This is known as the post-test carrier risk.
This report provides an estimate of the post-test carrier risk for people of French Canadian descent only.
Post-test carrier risk is based on the average chance of l::eing a carrier for a given ethnicity and the carrier detection rate of the test for a given ethnicity.
• For people of partial French Canadian descent, post-test carrier risk is less than that for those who are fully French Canadian. The exact post-test risk depends on how much French Canadian ancestry a person has.
• Post-test risk for other ethnicities cannot be provided because sufficient data is not available.
View technical article on estimating post-test carrier risk.
Indications for Use
Post-test carrier risk for relevant ethnicities
French Canadian, particularly from the Charlevoix and Saguenay-Lac-Saint-Jean regions of Quebec
Test Details
The 23andMe PGS Carrier Status Test for Agenesis of the Corpus Callosum with Peripheral Neuropathy is indicated for the detection of the T813fsX813 :,ariant in the SLC12A6 9E!I JE!. This test is intended to be used to determine carrier status for ACCPN in adults, but cannot determine if a person has two copies of a tested variant. The test is most relevant for people of French Canadian descent.
Special Considerations
• There are currently no professional guidelines in the U.S. for carrier testing for this condition. • Positive results in individuals whose ethnicities are not commonly associated with this condition may be incorrect.
Test Performance Summary
Individuals in this situation should consider genetic counseling and follow-up testing.
• Share results with your healthcare professional for any medical purposes.
• If you are concerned about your results, consult with a healthcare professional.
See the Package Insert for more details on use an:! performance of this test.
• V3nants not included 1n this test may be very rare, may not be available on our genotyping p,atform, or may not pass our test,ng standards.
